Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
暂无分享,去创建一个
M. Peacock | J. Humphrey | M. Klausner | Takahiro Ito | Xiaoping Zhang | T. Weber | K. Insogna | T. Carpenter | E. Imel | M. Ruppe | M. Wooddell | Tetsuyoshi Kawakami
[1] I. Holm,et al. A clinician's guide to X‐linked hypophosphatemia , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] T. Shimada,et al. Anti‐FGF‐23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] T. Shimada,et al. Therapeutic Effects of Anti‐FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] M. Mohammadi,et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. , 2009, American journal of physiology. Renal physiology.
[5] R. Kuroki,et al. Anti‐FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23 , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] L. Quarles,et al. How fibroblast growth factor 23 works. , 2007, Journal of the American Society of Nephrology : JASN.
[7] M. Econs,et al. Fibroblast growth factor 23: roles in health and disease. , 2005, Journal of the American Society of Nephrology : JASN.
[8] C. Ohlsson,et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. , 2004, Endocrinology.
[9] T. Yoneya,et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. , 2004, Biochemical and biophysical research communications.
[10] Y. Takeuchi,et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.
[11] C. Kleinman,et al. Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets. , 2001, Current opinion in pediatrics.
[12] W. A. Murphy,et al. X‐Linked Hypophosphatemia: A Clinical, Biochemical, and Histopathologic Assessment of Morbidity in Adults , 1989, Medicine.
[13] M. Gibaldi,et al. Noncompartmental Analysis Based on Statistical Moment Theory , 1982 .
[14] F. Glorieux,et al. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. , 1981, The Journal of clinical endocrinology and metabolism.
[15] O. Bijvoet,et al. NOMOGRAM FOR DERIVATION OF RENAL THRESHOLD PHOSPHATE CONCENTRATION , 1975, The Lancet.
[16] David S. Wishart,et al. The Online Metabolic and Molecular Bases of Inherited Disease; Chapter 3.1: Metabolism and Metabolic Disease Resources on the Web, Page 1 , 2007 .
[17] Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .